EMA CHMP recommends approval of linagliptin for type 2 diabetes
Links shared publicly online about this topic.
- 195total visits
EMA CHMP recommends approval of linagliptin for type 2 diabetes
Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.
View full resource at news-medical.net
Tags: Diabetes, Type 2 Diabetes, Eli Lilly and Company, Boehringer Ingelheim, Medical
Most Recently Shared on June 24, 2011 at 8:47 pm By:
EMA CHMP recommends approval of linagliptin for type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company ... http://bit.ly/kjFU5X
Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe | Business Wire
businesswire.com — “Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today received a positive opinion from the European Medicines Agency’s (EMA) medicinal” View full resource at businesswire.com
Most Recently Shared on June 24, 2011 at 2:45 pm By:
Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe: INGELHEIM, Germany--(BUSINES... http://bit.ly/jqrcRT
Advertisement
